Table 4 Myocardial blood flow changes in regions with or without dipyridamole‐induced perfusion defects.
| Group 1 | Group 2 | |||||
|---|---|---|---|---|---|---|
| Enrolment | 6 months (placebo) | p Value | Enrolment | 6 months (carvedilol) | p Value | |
| Dip+ regions | ||||||
| Rest MBF | 0.55 (0.15) | 0.53 (0.14) | NS | 0.56 (0.18) | 0.44 (0.19) | <0.001 |
| Dip‐MBF | 1.04 (0.37) | 0.87 (0.35) | NS | 1.07 (0.62) | 1.18 (0.62) | NS |
| CFR | 1.98 (0.74) | 1.65 (0.49) | NS | 1.82 (0.58) | 2.95 (1.91) | 0.02 |
| Dip− regions | ||||||
| Rest MBF | 0.68 (0.30) | 0.66 (0.29) | NS | 0.56 (0.22) | 0.59 (0.21) | NS |
| Dip‐MBF | 1.10 (0.52) | 1.07 (0.32) | NS | 1.22 (0.75) | 1.49 (0.63) | NS |
| CFR | 1.75 (0.88) | 1.81 (0.64) | NS | 2.19 (0.80) | 2.57 (0.92) | NS |
CFR, coronary flow reserve; Dip, dipyridamole; Dip+ region, showing dipyridamole‐induced perfusion defects at enrolment; Dip−, regions not showing Dip‐induced perfusion defects at enrolment; MBF, myocardial blood flow.